ImageneBio Inc (IMA) Stock

ImageneBio Inc (IMA) is a Healthcare stock trading at $5.58 (as of 2026-08-21), with a market capitalization of $63.34M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

ImageneBio Inc is a clinical-stage biotechnology company developing therapies for immunological, autoimmune, and inflammatory diseases. Its pipeline includes IMG‑007, a non-depleting anti‑OX40 monoclonal antibody currently in Phase 2b testing for atopic dermatitis.

Understand ImageneBio Inc: how it makes money

ImageneBio Inc develops clinical-stage biotechnology therapies for immunological and autoimmune inflammatory diseases, including its non-depleting anti-OX40 monoclonal antibody IMG-1007 (in Phase 2b for atopic dermatitis), and it makes money via collaboration revenue (which was 0.0B in the latest reported quarter).

In the absence of product revenue, the profit model is primarily driven by whether the company can generate collaboration revenue and translate clinical progress in its pipeline into future partnering and commercialization opportunities.

Revenue by segment (latest quarter)
Collab$0.0B

Business quality (Weak): Latest-quarter disclosure shows 0.0B revenue and a very negative operating margin, so investors should focus on clinical trial operating metrics and collaboration progress rather than near-term sales performance.

Bull case

  • Phase 2b clinical progress focus for IMG-1007: The company is developing IMG-1007, its non-depleting anti-OX40 monoclonal antibody, in Phase 2b for atopic dermatitis.
  • Clear, measurable trial activity indicators: Recent operational KPIs include Dose Escalation Patients Treated (IK-930) at 26.0 and Patients Treated Within Projected Efficacious Exposure Range (IK-930) at 15.0.

Bear case

  • No reported revenue in the latest quarter: Collaboration Revenue was 0.0B in the period ending 2025-03-31.
  • Heavy operating losses: Operating margin was -1349.2 in the latest reported quarter, which indicates substantial expense levels relative to revenue.
  • Clinical outcomes may not translate into business momentum: Key pharmacodynamic readouts are partial (for example, 80.0% ERK inhibition at 4 hours post dosing and 60.0% sustained through 24 hours), and not all treated patients are in the projected efficacious exposure range (15.0 vs 26.0).
Valuation — source: SEC EDGAR (first-party)
Price$5.58
Market Cap$63.34M
Price / Book0.45
Price / Sales12.42
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$800000.00
Net Margin-5668.6%
Revenue Growth (YoY)-77.1%
EPS Growth (YoY)845.1%
Financial Health — source: SEC EDGAR
Altman Z-Score-1.31 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBVF INC/IL ($5.55M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOKristin Yarema
Employees10
CountryUS
IPO Date1998-02-27

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • ProKidney Corp. (PROK)
  • Atara Biotherapeutics, Inc. (ATRA)
  • Champions Oncology, Inc. (CSBR)
  • Cardiff Oncology, Inc. (CRDF)
  • eXoZymes, Inc. (EXOZ)
  • INmune Bio, Inc. (INMB)
  • MiNK Therapeutics, Inc. (INKT)
  • Scilex Holding Company (SCLX)
IMA earnings history · IMA institutional & insider holders · IMA KPIs & operating metrics · IMA financials · IMA investor presentations & press releases · IMA SEC filings · IMA peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.